Last reviewed · How we verify
Emcyt (ESTRAMUSTINE PHOSPHATE)
Emcyt (Estramustine Phosphate) is a small molecule drug originally developed by Pharmacia and Upjohn, now owned by the same company. It targets Tyrosine-protein phosphatase non-receptor type 11 and is classified as an estramustine phosphate. Emcyt was FDA-approved in 1981 for certain indications, but its commercial status is off-patent with no active Orange Book patents. As a result, there are currently no generic manufacturers. Key safety considerations include its short half-life of 2.4 hours and moderate bioavailability of 44%.
At a glance
| Generic name | ESTRAMUSTINE PHOSPHATE |
|---|---|
| Sponsor | Pfizer |
| Drug class | estramustine phosphate |
| Target | Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2, Protein-tyrosine phosphatase 1C, Tyrosine-protein phosphatase non-receptor type 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (PHASE3)
- Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation (NA)
- Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
- Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer (PHASE2)
- Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (PHASE3)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |